Elicio announces positive recommendation by IDMC to continue ELI-002 Phase 2

Elicio Therapeutics (ELTX) announced that following the Independent Data Monitoring Committee’s, IDMC, pre-specified interim review of the unblinded safety and efficacy data in the Company’s Phase 2 AMPLIFY-7P study in mutant KRAS-driven pancreatic ductal adenocarcinoma, the IDMC recommended that the trial continue to the final analysis without modifications. In addition, the IDMC confirmed the favorable safety profile of ELI-002 7P to date. The Company views the IDMC’s positive recommendation as an indication that ELI-002 7P has shown preliminary signals of efficacy. The Company’s current cash runway extends into Q1 2026, past the anticipated final DFS analysis